RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
10.1007/s12253-011-9485-5
Saved in:
Main Authors: | Omar, M.F.M., Ito, K., Nga, M.E., Soo, R., Peh, B.K., Ismail, T.M., Thakkar, B., Soong, R., Ito, Y., Salto-Tellez, M. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/116580 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma
by: Pang, N.K.B., et al.
Published: (2014) -
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
by: Kim, H.R., et al.
Published: (2014) -
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian Lung adenocarcinomas
by: Toh, C.-K., et al.
Published: (2014) -
Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer
by: Nicole Tsang, Y.-H., et al.
Published: (2014) -
An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): Maximizing the diagnostic procedure and the use of low-volume lung biopsies
by: Lim, E.H., et al.
Published: (2011)